为治疗多发性骨髓瘤开发针对BCMA的双特异性自然杀伤细胞激活剂
Minchuan Zhang1, Han Ping Loh2, Shiyi Goh Fang2
1Singapore Immunology Network, Agency for Science, Technology and Research, Immunos Building, 8A Biomedical Grove, Singapore 138648, Singapore.
Antibodies (Basel, Switzerland)
|December 27, 2024
概括
针对BCMA的新双特异性NK细胞参与剂为多发性骨髓瘤治疗提供了更安全的替代方案. 优化它们的分子设计是提高疗效和减少患者副作用的关键.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 针对B细胞成熟抗原 (BCMA) 的免疫疗法,如CAR T细胞,在多发性骨髓瘤 (MM) 中表现出成功.
- 过度激活T细胞会导致严重的副作用,包括细胞因子释放综合征和神经毒性.
- 双特异性NK细胞参与剂 (NKCEs) 通过使用NK细胞提供了一个替代方案,可能避免这些毒性.
研究的目的:
- 设计和评估用于向多发性骨髓瘤的新型BCMA × CD16NKCE.
- 调查分子格式对NKCE功能的影响.
主要方法:
- 设计了一系列BCMA × CD16 NKCE.
- 在基于分子设计的实验室中评估NKCE功能.
主要成果:
- NKCE 的格式设计显著影响其功能.
- 这凸显了格式选择对于优化基于NKCE的疗法的重要性.
结论:
- NKCE 是对多发性骨髓瘤的一种有前途的治疗策略.
- 进一步开发NKCE可能会导致改善MM和其他癌症的治疗方法.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Tumor Immunotherapy
394
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
394
Combination Therapies and Personalized Medicine
4.7K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.7K
Hybridoma Technology
13.7K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
13.7K
B Cell Activation and Differentiation
1.2K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.2K


